Biography
Prof Stellah Mpagama is a physician scientist and Director of Research and Innovation at Kibong'oto Infectious Diseases Hospital, Tanzania. Prof Mpagama studies all aspects of clinical tuberculosis including epidemiology, health systems management, diagnostics, therapeutics and post-TB disability. She is part of multiple international consortia for clinical trials among people with TB and populations impacted by TB.
Key Impacts
Six-month mortality in ATLAS trial of immediate and/or high-dose anti-TB therapy for adults with HIV-related sepsis
Immediate conventional-dose anti-TB therapy significantly reduced 6-month mortality in those later confirmed to have TB, comprising the majority of the population. Further studies should consider the optimal timing of anti-TB discontinuation in those that survive sepsis without later diagnostic confirmation of TB.
Source: Conference 2024